Stock Splits
By The Online Investor Staff, updated Tue., May. 24, 9:02 AM
| This Slide: #6 of 25 |
Slide #6. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) — 1 for 32 Reverse Split
Announced:
5/16/2022
Stock Split:
1 for 32
Record Date:
5/16/2022
Pay Date:
5/17/2022
TNXP Optionable?:
No
Tonix Pharmaceuticals Holding is a clinical-stage biopharmaceutical company focused on discovering, cquiring and developing therapeutics and diagnostics to treat and prevent human disease. Co.'s portfolio is primarily composed of immunology, central nervous system (CNS), and infectious disease product candidates. Co.'s key product candidate within its immunology pipeline is TNX-1500, a humanized monoclonal antibody, directed against CD40-ligand, engineered to modulate binding to Fc receptors, that is being developed as a prophylaxis against organ transplant rejection. Among the CNS candidates in development is TNX-1300 which is for the treatment of life-threatening cocaine intoxication.
TNXP SEC Filing Email Alerts Service
TNXP Detailed Information Page & Split History »
|
||||||||||||||||||||||||
Open the TNXP Page at The Online Investor (in a new window) »
 Free TNXP Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 69th percentile
(ranked higher than approx. 69% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
